Our goal is to become a fully integrated biotechnology company. We will achieve this by developing and ultimately commercializing transformative Anticalin-based therapeutics to treat challenging immunology-related diseases. Pieris is building its development expertise in collaboration with industry leaders and has most recently signed two strategic alliances: an immuno-oncology (IO) partnership with Servier and a respiratory disease-focused collaboration with AstraZeneca. In both cases, Pieris retains certain development and commercial rights to specific products and in specific regions, as part of Pieris’ long-term strategy to market novel therapeutics in the USA. Beyond these and other partnerships, Pieris is advancing fully proprietary programs, including its lead IO bispecific, PRS-343, a first-in-class tumor-targeted T cell agonist.
Key elements of our strategy include:
- Developing and broadening our core franchises in Immuno-Oncology and Respiratory Disease
The two core therapeutic areas for the Company, respiratory disease and immuno-oncology, are anchored by major alliances. Pieris nonetheless retains the right to seek additional partnerships within these therapeutic areas, allowing us to further strengthen our core focus areas through collaboration. In immuno-oncology, Pieris is independently pursuing a number of candidates including the most advanced development candidate in oncology, PRS-343, a bivalent, bispecific fusion protein targeting CD137 (4-1BB) and HER2.
- Continuing to build our platform by entering into new partnerships and advancing our currently-partnered programs
We have active partnerships across a diverse range of therapeutic areas and geographies. Our partners include global pharmaceutical companies, such as AstraZeneca, Seattle Genetics and Servier. Together with these partners, we intend to advance multiple drug candidates through preclinical and clinical studies. As we continue to advance the Anticalin platform technology, we will continue to consider entering additional collaborations with partners that want to combine their disease and target know-how with our ability to generate highly differentiated next-generation Anticalin therapeutic protein drug candidates.